More recently, it has also been demonstrated that recombinant LIF therapy can reduce the number of Th17 cells in the spleen and CNS of mice with EAE, and inhibit the differentiation of Th17 cells from human MS cases [35] in vitro. This evidence concerns the gene LIF and myeloid sarcoma.